Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Interest Expenses (2016 - 2017)

Capricor Therapeutics has reported Interest Expenses over the past 7 years, most recently at $80307.0 for Q4 2017.

  • Quarterly results put Interest Expenses at $80307.0 for Q4 2017, down 21.96% from a year ago — trailing twelve months through Sep 2018 was $80307.0 (down 80.94% YoY), and the annual figure for FY2025 was $3.0 million, changed.
  • Interest Expenses for Q4 2017 was $80307.0 at Capricor Therapeutics, down from $107653.0 in the prior quarter.
  • Over the last five years, Interest Expenses for CAPR hit a ceiling of $107653.0 in Q3 2017 and a floor of $3711.0 in Q1 2013.
  • Median Interest Expenses over the past 5 years was $61681.0 (2015), compared with a mean of $64519.9.
  • Biggest five-year swings in Interest Expenses: surged 780.76% in 2014 and later fell 21.96% in 2017.
  • Capricor Therapeutics' Interest Expenses stood at $23353.0 in 2013, then surged by 158.57% to $60383.0 in 2014, then rose by 5.3% to $63583.0 in 2015, then soared by 61.84% to $102905.0 in 2016, then decreased by 21.96% to $80307.0 in 2017.
  • The last three reported values for Interest Expenses were $80307.0 (Q4 2017), $107653.0 (Q3 2017), and $105527.0 (Q2 2017) per Business Quant data.